Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

IceCure Medical (ICCM) Gains from Sales and Divestitures (2025)

IceCure Medical has reported Gains from Sales and Divestitures over the past 1 years, most recently at $288764.0 for Q4 2025.

For Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $288764.0; the TTM value through Dec 2025 reached $288764.0, changed N/A, while the annual FY2025 figure was $288764.0, N/A changed from the prior year.
Gains from Sales and Divestitures was $288764.0 for Q4 2025 at IceCure Medical.
Across five years, Gains from Sales and Divestitures topped out at $288764.0 in Q4 2025 and bottomed at $288764.0 in Q4 2025.